Pathogenesis of myeloma bone disease

被引:0
作者
G D Roodman
机构
[1] Veterans Affairs Pittsburgh Healthcare System,Department of Medicine/Hematology
[2] University of Pittsburgh,Oncology
来源
Leukemia | 2009年 / 23卷
关键词
multiple myeloma; osteoclast; osteoblast; bone disease;
D O I
暂无
中图分类号
学科分类号
摘要
Bone disease in multiple myeloma (MM) is characterized by lytic bone lesions, which can cause severe bone pain, pathologic fractures and hypercalcemia. However, the lytic bone disease in MM differs from that in other cancer patients who have lytic bone metastases. Although increased osteoclastic bone destruction is involved in MM and other tumors involving bone, in contrast to other tumors, once the MM tumor burden exceeds 50% in a local area, osteoblast activity is either suppressed or absent.1 The basis for this severe imbalance between increased osteoclastic bone resorption and decreased bone formation has been a topic of intensive investigation over the last several years and will be reviewed in this article.
引用
收藏
页码:435 / 441
页数:6
相关论文
共 393 条
[61]  
Nakano A(2001)Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2 Curr Treat Options Oncol 2 271-1228
[62]  
Cackowski FC(2006)Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation Clin Cancer Res 12 1221-1639
[63]  
Roodman GD(2007)Wnt signalling in osteoblasts regulates expression of the receptor activator of NFkappaB ligand and inhibits osteoclastogenesis Blood 118 1054A-1782
[64]  
Hsu H(2006)Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group Eur J Cancer 42 1623-73
[65]  
Lacey DL(2003)Bone disease in myeloma J Clin Invest 111 1771-238
[66]  
Dunstan CR(2005)A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer Br J Haematol 131 71-1467
[67]  
Solovyev I(2006)An open label phase 2 trial of Denosumab in the treatment of relapsed or plateau-phase myeloma Eur J Haematol 77 233-338
[68]  
Colombero A(2003)Proteasome inhibition in multiple myeloma Leuk Lymphoma 44 1463-438
[69]  
Timms E(2007)Selective inhibitors of the osteoblast proteasome stimulate bone formation Blood 110 334-692
[70]  
Nakagawa N(2007) and Br J Haematol 139 434-1622